http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#Head
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#assertion
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#provenance
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#pubinfo
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#assertion
http://purl.obolibrary.org/obo/DOID_3310
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_3310
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00591
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#association
http://www.w3.org/2000/01/rdf-schema#label
fluocinolone acetonide topical oil is a corticosteroid indicated for the topical treatment of atopic dermatitis in adult patients 1 1 topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to 4 weeks 1 2 limitations of use apply the least amount to cover affected areas discontinue when disease is controlled 1 3 do not use in the diaper area 1 3 do not use on the face axillae or groin 1 3 6 2 8 4 fluocinolone acetonide topical oil is indicated for the topical treatment of atopic dermatitis in adult patients fluocinolone acetonide topical oil is indicated for the topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to 4 weeks safety and effectiveness in pediatric patients younger than 3 months of age have not been established apply the least amount of fluocinolone acetonide topical oil needed to cover the affected areas as with other corticosteroids fluocinolone acetonide topical oil should be discontinued when control of disease is achieved contact the physician if no improvement is seen within 2 weeks fluocinolone acetonide topical oil should not be applied to the diaper area diapers or plastic pants may constitute occlusive use fluocinolone acetonide topical oil should not be used on the face axillae or groin unless directed by the physician application to intertriginous areas should be avoided due to the increased risk of local adverse reactions see adverse reactions 6 use in specific populations 8 4
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00591
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#provenance
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#pubinfo
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#sig
http://purl.org/nanopub/x/hasSignature
dhPjKHDgRl04VP4r8coGQM2wjZ5Xvu7O7oDJhOLFttjd0x8QiqwT1ZoeYRQF9PAbEm3/egcj8TDLZ08Yg5dW8Bxbd80DC7j7/f1PKCBQxX6EMja/ZLdMeNtUB1LjOyKAXzQl3Uu1beCeid1iPthRKv3kVX44pEbKjdxGEi505kY=
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ
http://purl.org/dc/terms/created
2021-06-27T20:42:27.644+02:00
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RA008X0dUg5AD2B4k0MTAUQ0vhJjAu3cbS8VSqymcqatQ
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs